SwanBio Therapeutics has raised $56 million in a second-round financing that will be used to advance its lead gene therapy candidate for adrenomyeloneuropathy (AMN) into clinical testing later ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback